Form 4: Upstream Bio CMO Receives Equity Compensation

Upstream Bio's Chief Medical Officer, Aaron Deykin, was granted 32,000 restricted stock units and options for 96,000 shares of common stock.

Summary

• Aaron Deykin, Chief Medical Officer of Upstream Bio, Inc. (UPB), was granted 32,000 restricted stock units (RSUs) on January 2, 2026.
• Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting.
• The RSUs will vest in sixteen equal quarterly installments following January 1, 2026, contingent on continued service.
• Deykin also acquired options to buy 96,000 shares of Common Stock with an exercise price of $27.07 per share on January 2, 2026.
• These stock options will vest in forty-eight equal monthly installments following January 1, 2026, subject to continued service.
• Following these transactions, Deykin beneficially owns 33,581 shares of Common Stock, which includes 1,581 shares previously acquired under the Issuer's 2024 Employee Stock Purchase Plan.
• The stock options have an expiration date of January 1, 2036.

Sentiment

Score: 6

Explanation: The filing indicates a positive alignment of management and shareholder interests through equity compensation, which is a standard and generally favorable practice for executive retention and motivation. It does not contain negative news, but also no immediate operational or financial breakthroughs.

Positives

• The equity grants align the Chief Medical Officer's financial interests with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options promote executive retention and continued service to the company.

Future Outlook

The grants of restricted stock units and stock options are subject to vesting schedules extending over several years (16 quarterly installments for RSUs, 48 monthly installments for options), contingent on Aaron Deykin's continued service to Upstream Bio, Inc. This indicates an expectation of his ongoing role and contribution to the company's future performance.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries. It is commonly used to attract, retain, and incentivize key executives and employees, aligning their long-term interests with the company's success and shareholder value creation.

Comparison to Industry Standards

• The use of restricted stock units and stock options for executive compensation is a common practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Moderna, BioNTech, or Regeneron, which frequently utilize equity to incentivize leadership.
• Vesting schedules, such as quarterly or monthly installments over several years, are typical for executive equity grants, designed to promote long-term commitment and performance, similar to those observed in other growth-oriented life science companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the Chief Medical Officer's long-term interests with shareholder value creation, potentially leading to more focused strategic decisions.
• Employees: The existence of equity compensation plans (2024 Stock Option and Incentive Plan, 2024 Employee Stock Purchase Plan) suggests a structured approach to employee incentives and retention.

Next Steps

• Aaron Deykin's continued service to Upstream Bio, Inc. is required for the vesting of the restricted stock units and stock options.

Key Dates

Keywords

Upstream Bio, UPB, Aaron Deykin, Chief Medical Officer, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4